New hope for blistering skin diseases: drug targets harmful antibodies to heal wounds
NCT ID NCT07011589
First seen May 08, 2026 · Last updated May 08, 2026
Summary
This study tests whether a drug called efgartigimod can lower harmful antibodies that attack the skin in two rare blistering diseases: recessive dystrophic epidermolysis bullosa (RDEB) and epidermolysis bullosa acquisita (EBA). About 18 participants aged 12 and older will receive the drug to see if it helps wounds heal faster and reduces disease activity. The goal is to improve quality of life by decreasing painful blisters and sores.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for RECESSIVE DYSTROPHIC EPIDERMOLYSIS BULLOSA are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Stanford University
Redwood City, California, 94163, United States
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact
Conditions
Explore the condition pages connected to this study.